New Phase 3 Data Announced on Efficacy of Tapinarof for Adul

These new, positive data from the ADORING Phase 3 development program showed no new safety signals with long-term use as well as a significant reduction in disease burden.

Related Keywords

Oregon , United States , Philip Brown , Eric Simpson , Eczema Center , Dermavant Sciences , Drug Administration , Oregon Health Science University , Eczema Area , Severity Index , Oregon Health , Science University , Validated Investigator Global Assessment , Atopic Dermatitis , Maximal Usage Pharmacokinetics , Chief Medical Officer , Eczema , Sad , Tapinarof , Vtama , Dermavant ,